On October 31, 2017 Alkermes plc (NASDAQ: ALKS) reported that its corporate presentation will be webcast live at the Credit Suisse 26th Annual Healthcare Conference on Tuesday, Nov. 7, 2017 at 9:45 a.m. MT (11:45 a.m. ET/4:45 p.m. GMT) from The Phoenician in Scottsdale, AZ (Press release, Alkermes, OCT 31, 2017, View Source;p=RssLanding&cat=news&id=2312944 [SID1234521365]). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on Alkermes’ Cancer Pipeline, book your free 1stOncology demo here.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

On October 31, 2017 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) reported that it will report its third quarter financial results after market close on Tuesday, November 7, 2017 (Press release, Rigel, OCT 31, 2017, View Source [SID1234521354]). Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 4894258. The conference call will also be webcast live and can be accessed from Rigel’s website at www.rigel.com. The webcast will be archived and available for replay after the call via the Rigel website.

On November 1, 2017 Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, reported that it will hold a conference call on Thursday, November 2, 2017 at 1:15 PM Pacific Time (4:15 PM Eastern Time) to discuss third quarter 2017 financial results and provide a corporate update (Press release, Arbutus Biopharma, OCT 31, 2017, View Source [SID1234521380]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Speakers will include:

Dr. Mark Murray, President and Chief Executive Officer
Dr. Mike Sofia, Chief Scientific Officer
Dr. Bill Symonds, Chief Development Officer
Mr. Bruce Cousins, Executive Vice President and Chief Financial Officer
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus’ website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 1177108.

On October 31, 2017 Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, reported that overall survival data from two Phase I clinical trials of its wholly owned, lead programme, IMCgp100, in metastatic uveal melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 32nd Annual Meeting (Press release, Immunocore, OCT 31, 2017, View Source [SID1234521335]). This year’s SITC (Free SITC Whitepaper) is taking place 8 – 12 November, 2017, at the Gaylord National Resort & Convention Center in National Harbor, Maryland in USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Information:
Title: Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials
Authors: Richard Carvajal, Takami Sato, Alexander N. Shoushtari, Joseph Sacco, Paul Nathan, Marlana Orloff, Pippa Corrie, Neil Steven, Jeff Evans, Jeffrey Infante, Mario Sznol, Clive Mulatero, Omid Hamid, Leonel Hernandez-Aya, Nicola Little, Cheryl McAlpine, David Krige, Namir J. Hassan, Sanjay Patel, Ann-Marie Hulstine, Christina M. Coughlin, Mark R. Middleton
Category: Clinical Trials (Completed)
Date: Saturday 11 November 2017
Time: 12:30 – 14:00 & 18:30 – 20:00
Abstract Number: P208

The details of the clinical trial can be found on clinicaltrials.gov.

Furthermore, a poster presenting findings from a study mapping the treatment pathway for patients with metastatic uveal melanoma in England will be presented.

Title: Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study
Authors: Elisabeth Adams, Chih-Yuan Cheng, Joseph Sacco, Sarah Danson, Pippa Corrie, Paul Nathan, Peter Szlosarek, Joanne Upton, Abolore Amuludun, Toby Toward
Category: Best Practices for Improving Cancer Immunotherapy Treatment Administration and Polypharmacy Management
Date: Friday 10 November 2017
Time: 12:30 – 14:00 & 18:30 – 20:00
Abstract: P437

To view the posters, please visit the SITC (Free SITC Whitepaper) website at View Source

SITC is the world’s leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Intellia Therapeutics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Intellia Therapeutics, 2017, OCT 31, 2017, View Source [SID1234521345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!